Welgene Biotech Co (ROCO:6661) Total Equity: NT$286.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6661 Welgene Biotech Co Ltd ROCO:6661
70 GF Score
Price NT$17.55
GF Value NT$29.93
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Welgene Biotech Co Total Equity?

Welgene Biotech Co ROCO:6661 70 Total Equity is NT$286.1 Mil as of Dec. 2025. GuruFocus rates ROCO:6661 with a GF Score™ of 70/100 and a GF Value™ of NT$29.93 (Possible Value Trap). The stock has 6 warning signs investors should review.

Welgene Biotech Co's total equity for the quarter that ended in Dec. 2025 was NT$286.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Welgene Biotech Co Total Equity Historical Data

* Premium members only.

The historical data trend for Welgene Biotech Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Welgene Biotech Co Total Equity Chart

Welgene Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 310.06 303.95 300.27 295.75 286.07

Welgene Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 295.75 288.09 287.19 293.47 286.07
ROCO:6661
70GF Score
Welgene Biotech Co Ltd ROCO:6661
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Welgene Biotech Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Welgene Biotech Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=622.193-336.119
=286.1

Welgene Biotech Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=622.193-336.119
=286.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$286.1 Mil mean?
Welgene Biotech Co (ROCO:6661) has a Total Equity of NT$286.1 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Welgene Biotech Co and its competitors.
Is Welgene Biotech Co's Total Equity too high?
Welgene Biotech Co's current Total Equity is NT$286.1 Mil. Overall, Welgene Biotech Co has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Welgene Biotech Co's Total Equity compare to TMO and DHR?
Welgene Biotech Co's Total Equity of NT$286.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Welgene Biotech Co and its competitors. Welgene Biotech Co's current Total Equity is NT$286.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welgene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Welgene Biotech Co (ROCO:6661) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.93, compared to a current price of NT$17.55 — trading 41.4% below its estimated fair value. The current Total Equity is NT$286.1 Mil. Welgene Biotech Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Welgene Biotech Co (ROCO:6661), the current Total Equity is NT$286.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Welgene Biotech Co (ROCO:6661) Overvalued in 2026?

Based on GuruFocus' analysis, Welgene Biotech Co stock appears to be undervalued. The current stock price of NT$17.55 is trading 41.4% below its estimated GF Value™ of NT$29.93. GuruFocus considers Welgene Biotech Co to be Possible Value Trap.

Key valuation signals for ROCO:6661:

  • Total Equity: NT$286.1 Mil
  • GF Value™: NT$29.93 vs. price of NT$17.55 (41.4% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Welgene Biotech Co Business Description

Address No. 3, Yuanqu Street, 12th Floor, Nangang District, Taipei, TWN, 115603
Welgene Biotech Co Ltd is engaged in providing genetic and biotechnology testing services and related products. Its offerings include next-generation sequencing (NGS) services, DNA microarray and PCR-based testing solutions, biotechnology reagents, diagnostic products, and laboratory instruments. The company also engages in the trading of medical and biotechnology equipment.
70GF Score

Get the complete analysis for ROCO:6661

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.55
Price
NT$29.93
GF Value